Navigation Links
ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
Date:8/25/2009

IRVINE, Calif., Aug. 25 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced positive preliminary Phase 3 results from the Company's Xibrom((TM)) (bromfenac ophthalmic solution) 0.09% QD (once-daily) confirmatory clinical study. Xibrom 0.09% QD achieved statistical significance in the study's primary endpoint, the absence of ocular inflammation 15 days following cataract surgery, and the secondary efficacy endpoint, the elimination of ocular pain one day post surgery. During the study, no serious ocular or systemic adverse events occurred, and the safety profile is consistent with ISTA's currently marketed Xibrom twice-daily formulation.

The confirmatory Phase 3 study was a multi-center, randomized, double-masked, parallel-group study in 299 patients who underwent cataract surgery in one eye. Patients were assigned randomly (1:1) to receive either Xibrom once daily or placebo. Dosing began one day before cataract surgery and continued for 14 days following surgery. The proportion of patients experiencing no pain was assessed at Day 1 post surgery, and the proportion of patients with complete absence of ocular inflammation was assessed at Day 15 post surgery. Ocular inflammation was evaluated using a summed ocular inflammation score (SOIS) and was measured by an assessment of immune cells in the anterior chamber of the eye ("cells") and cellular debris ("flare"). The secondary efficacy endpoint was evaluated via a pain score from the Ocular Comfort Grading Assessment recorded in a diary. Patients also graded their symptoms at each office visit, which included photophobia, the chief symptomatic complaint following cataract surgery.

In December 2008, ISTA announced integrated results from two Phase 3 studies with Xibrom 0.09% QD. Based on th
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a biopharmaceutical ... that David J. Haen , Vice President, Business ... Biotech Industry Conference on Friday, September 26 th at ... at the Millennium Broadway Hotel in New ... archived webcast of the presentation will be available on ...
(Date:9/18/2014)... , Sept. 18, 2014  Low T Center ... meeting in Hyattsville, Maryland ... assess the proper patient population for testosterone therapy ... risk associated with TRT. Examining recent claims from studies ... that "available epidemiological studies do not provide convincing ...
(Date:9/18/2014)...   MacPractice,s MacPractice MD MU version 5.0 ... which designates that the software is capable of supporting ... 2 Meaningful Use measures required to qualify for funding ... MD MU version 5.0 was certified on June 6, ... the National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... today announced that The New England Journal ... II data for the investigational drug iniparib* (BSI-201) ... triple negative breast cancer (mTNBC) when iniparib was ...
... 2011 MiMedx Group, Inc.  (OTC Bulletin ... and marketer of patent protected biomaterial-based products, announced today ... leader in the development of tissue processing techniques for ... amnion membranes. The deal was originally announced on December ...
Cached Medicine Technology:Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 2Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 3Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 4Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 5Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 6MiMedx Completes Acquisition of Surgical Biologics 2MiMedx Completes Acquisition of Surgical Biologics 3MiMedx Completes Acquisition of Surgical Biologics 4
(Date:9/19/2014)... NY (PRWEB) September 20, 2014 As summer ... Krishnan DMD in Queens, NY now reminds area patients about ... than 80% of our population affected by gum disease, there ... longer.” , For over 20 years Dr. Krishnan has treated ... Hills office location. “Most patients that come in due to ...
(Date:9/19/2014)... collaborative research team led by Medical College of Wisconsin (MCW) ... and insulin levels in rats, mice and in humans. The ... Genetics . , Leah Solberg Woods, Ph.D., associate ... Children,s Hospital of Wisconsin Research Institute, led the study and ... of the paper identified a gene called Tpcn2 in which ...
(Date:9/19/2014)... Albany,NY (PRWEB) September 19, 2014 ... Dr. Reed Ference, is excited to announce the ... with periodontal disease, gingivitis and those needing dental ... the LANAP® laser treatment removes the fear factor ... no stitches, less discomfort and bleeding make, this ...
(Date:9/19/2014)... 2014 York University researchers say a simple ... to detect heightened risk for developing Alzheimer,s disease ... telltale behavioural signs of dementia., Faculty of Health ... who led the study asked the participants to ... on dual screen laptop computers. The test aimed ...
(Date:9/19/2014)... 2014 Recent financial data reveled ... increased their sales by 7% in the last quarter ... industry can be used as a bellwether to determine ... This data has been proven to show trends with ... transportation. Other non-trucking data is largely influenced by international ...
Breaking Medicine News(10 mins):Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3Health News:Simple test can help detect Alzheimer's before dementia signs show: York U study 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3
... , Recent CBO analysis ... 3 A new actuarial analysis by Oliver Wyman, Inc. ... market will be 54 percent higher than they are today ... Protection and Affordable Care Act (PPACA), excluding the impact of ...
... a new factor that is necessary for the development ... of malignant childhood brain cancer. HHMI investigator Huda Y. ... medulloblastoma from developing in mice by shutting down production ... team,s findings, reported in the December 4, 2009, issue ...
... , NEW YORK, Dec. ... H1N1/09 Type A influenza ("Swine Flu") has reached a pandemic ... at least 6,500 fatalities. Since there is no longer ... undoubtedly understate the real situation. , (Photo: ...
... , CHICAGO, Dec. 3 An ... called platelet-rich plasma therapy (PRP), is showing strong potential ... a prominent dental researcher and editor of the ... Rutkowski, DMD, PhD, reported at the recent annual scientific ...
... low number of new cases created by a single ... as vaccination, social distancing and the use of antiviral ... the virus, suggests an epidemiological modelling study http://www.cmaj.ca/cgi/doi/10.1503/cmaj.091807 ... Medical Association Journal ) www.cmaj.ca . ...
... ... specializing in the emerging medical travel space, announced that international medical quality authority, Dr. ... ... 2009 –- Satori World Medical, a leading global healthcare company specializing in the emerging ...
Cached Medicine News:Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 2Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 3Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 4Health News:Researchers identify gene that spurs deadly brain cancer 2Health News:Researchers identify gene that spurs deadly brain cancer 3Health News:Buchang Global Health Forum 2009: An Innovative Approach for Management of H1N1 Swine Flu 2Health News:Platelet-rich Plasma Enhances Bone and Tissue Growth for Dental Implants 2Health News:Vaccination, antivirals and social distancing may blunt impact of H1N1 influenza 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 3Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: